Pharma Times -- The Wellcome Trust’s investment division has agreed a £20 million Series A equity financing for Kymab, a biopharmaceutical company spun out from the Trust’s Sanger Institute in Cambridge, UK and focused on the discovery, development and commercialisation of novel antibody-based medicines.
